351 results about "Serum antibody" patented technology

The present invention relates to methods and compositions for detecting and/or measuring serum antibodies to antigenic proteins in a sample, comprising adding a labeled antigenic protein or fragment thereof to a sample derived from serum and expected to contain serum antibodies and measuring differences in at least one characteristic between (a) a labeled serum antibody-antigenic protein complex; (b) an serum antibody-antigenic protein complex in the sample; and/or (c) displaced lableled or unlabeled serum antibody, antigenic protein or fragment thereof.

The present invention discloses the use of the non-toxic cell-binding B subunit of CT (CTB), and holotoxin CT that is devoid of ADP-ribosylating activity, as adjuvants for enhancing transcutaneous immune response to a co-administered protein allergen. It was found that topical administration of CTB to mice induced serum antibody response against itself comparable to those evoked by CT, but was inefficient at promoting systemic antibody responses against an admixed prototype protein allergen. To the contrary co-administration of either CT or CTB with allergen led to vigorous antigen-specific T cell proliferative responses in lymph nodes draining the cutaneous site of administration and at distant systemic sites. Consistent with these observations, it was found that CTB selectively potentiated Th1-driven responses without affecting Th2-dependent responses. Cutaneously applied CT enhanced serum IgE responses to a co-administered allergen, while CTB partially suppressed epicutaneously induced IgE responses to the same allergen.

Novel bactericidal antibodies against Neisseria meningitidis serogroup B (“MenB”) are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique epitopes found on MenB or E. coli K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody.

The invention relates to a polypeptide immunoassay kit, which comprises a protein G or protein A agarose serving as a solid phase carrier, a purified serum polypeptide antibody and PBS buffer solution. The invention also relates to a polypeptide immunomic spectrometry analysis method, which comprises the following steps: coupling a purified serum antibody with a proper solid carrier; allowing the coupled product to bond with a polypeptide marker antigen specifically, and separating the antigen from the carrier by using eluent; and finally, detecting polypeptide antigen in the eluent by high-pass matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOFMS). Thus, the complete immunomic spectrometry analysis method is established.

The invention relates to an enzyme-linked immunosorbent assay (ELISA) kit for duck hepatitis virus type-I serum antibody and relates to a test method and application of the kit. The kit comprises an enzyme label plate coated by the recombinant VP1 (virus protein) protein, a rabbit anti-duck IgY antibody marked by horseradish peroxidase, a TMB substrate colour reagent, a positive serum, a negative serum and a kit specification. In the invention, by adopting the polymerase chain reaction, the VP1 genes are amplified from the DHV-1genome and the VP1 gene-containing recombinant expression plasmid pET32a-VP1 is constructed; the plasmid is transferred to host cells BL21 (DE3), and the in-vitro expression VP1 protein is purified by a nickel column and then used as the antigen; the enzyme-linked immunosorbent assay kit is established; the positive serum is the standard positive serum of duck hepatitis virus type-I and the negative control is the standard negative serum of duck. The test kit has the advantages of strong specificity, high sensitivity, simple operation, easy large-scale popularization and application, very important application value in diagnosis of duck hepatitis virus type-I, survey of epidemiology and immunization survey and the like.

The invention relates to a test strip for detecting colibacillus O157:H7 mouse serum antibody by colloidal gold immunochromatography, belonging to the technical field of antibody detection kits and consisting of colloidal gold cushion prepared by utilizing a colloidal gold solution the granule of which is 20nm to mark purified sheep anti-mouse IgG, nitric acid cellulose films which are respectively coated by a colibacillus O157:H7 antigen and purified mouse serum IgG and serve as a detection line and a quality control line, a detection test strip formed by assembling a sample absorbing cushionprepared from glass cellulose films and an absorbing cushion made of water absorbing filter paper, positive serum, negative serum, a serum sample diluent and a test strip operating instruction. The test strip is convenient to use, rapid and sensitive, and a detection result can be obtained within 10 minutes, and therefore, the test strip is suitable for on-site detection when infection status ofmouse O157:H7 is surveyed and traced back in animal farmer areas, food production enterprise areas and the like and use when the food safety environment risk evaluation is carried out.

This invention relates to conjugates of the O-specific polysaccharide of E. coli O157 with a carrier, and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in mammals, including responses which provide protection against, or reduce the severity of, bacterial infections. More particularly it relates to the use of polysaccharides containing the tetrasaccharide repeat unit: (→3)-α-D-GalpNAc-(1→2)-α-D-PerpNAc-(1→3)-α-L-Fucp-(1→4)-β-D-Glcp-(1→), and conjugates thereof, to induce serum antibodies having bactericidal (killing) activity against hemolytic-uremic syndrome (HUS) causing E. coli, in particular E. coli O157. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies which have bactericidal or bacteriostatic activity against against E. coli, in particular E. coli O157, and are useful to prevent and/or treat illnesses caused by E. coli O157.

The invention further relates to the antibodies which immunoreact with the O-specific polysaccharide of E. coli O157 and/or the carrier, that are induced by these conjugates and/or compositions thereof. The invention also relates to methods and kits using one or more of the polysaccharides, conjugates or antibodies described above.

The invention relates to gene expression profiling technology to quantitatively measure the expression profiles of genes selected based on their role in inflammation and their susceptibility to regulation by current multiple sclerosis (MS) treatment agents, beta-interferon (IFN) and glatiramer acetate (GA). The invention also provides an assay for detection of beta-IFN neutralizing antibody based on the blocking effect of serum antibodies on the known regulatory properties of beta-IFN on PBMC and evaluation of treatment responses in MS patients.

The invention relates to a syphilis serological screening or diagnosis method. The purpose is that the method has the characteristics of low price, high speed, sensitivity and specificity. The technical scheme provided by the invention is that: a preparation method of rTpN15-17-47-ELISA for detecting syphilis serum antibodies comprises the following steps in turn: constructing an artificial fusion gene tpN15-17-47 of tpN15, tpN17 and tpN47 and a prokaryotic expression system E.coliBL21DE3Pet42a-tpN15-17-47 by gene technology, purifying the recombinant expression product rTpN15-17-47 as a coating antigen, establishing rTpN15-17-47-ELISA for detecting syphilis serum antibodies. The fusion gene tpN15-17-47 has a nucleotide sequence and an amino acid sequence as shown in sequence table 5.

The invention provides a PED (Porcine Epedemic Diarrhea) inactivated vaccine and a preparation method thereof and relates to the field of biopharmacy. The PED inactivated vaccine comprises inactivated PEDV (Porcine Epedemic Diarrhea Virus), and is characterized in that the PED inactivated vaccine comprises 0.05-10 mg/mL Beta-glucosylceramide, 0.1-21 mg/mL monophosphoryl lipid A, 1.5-125 mg/mL muramyl dipeptide and 0.7-4.5 mg/mL Beta-glucan. According to the ingredients of the PED inactivated vaccine, Beta-glucosylceramide, monophosphoryl phosphoryl lipid A, muramyl dipeptide and Beta-glucan have the synergistic effect, the immune response of animals to antigens in the vaccine is significantly improved, the immune window phase is shortened, the antibody production duration of the animal body is obviously prolonged, the serum antibody level is improved, and the level of total intestinal mucosa secretory antibodies (the total SIgA) is improved.

The invention discloses a method for preparing a bivalent yolk antibody for preventing and treating duck virus hepatitis I and III. The bivalent yolk antibody can be used for effectively preventing and treating the duck virus hepatitis I and III single and mixed infection and solving the problems that the existing vaccines, serum antibodies and yolk antibodies are not effective to the mixed infection. In addition, the bivalent yolk antibody is extracted by adopting a caprylic acid precipitation method. The method is safe, low in cost and suitable for mass production. The prepared bivalent yolk antibody has high purity and high titer, is stable in nature and is easy for storage.

The invention relates to a porcine rotavirus delta VP8* subunit recombinant protein and an encoding gene of the protein. The invention further provides a recombinant protein formed after increasing tetanus toxin T cell epitope P2 into the recombinant protein, and an encoding gene. The delta VP8* protein is 64th-site to 223th-site amino acid in the VP8* and can effectively stimulate an organism to produce specific serum antibody, humoral immune response is good, the problem that the VP4 gene can not conduct prokaryotic expression due to overlarge fragment can be overcome, the protein can be expressed as a soluble protein in vitro, so that the problem that the VP8* is expressed as an inclusion body in vitro can also be overcome; the T cell epitope P2 (830th-site to 844th-site amino acid of TT) in the tetanus toxin is induced into the delta VP8* subunit recombinant protein, so that the immunity efficacy of the protein can be greatly improved, the faster and stronger neutralizing antibody titer can be induced, and high-titer rotavirus cross neutralizing antibody can also be induced.

The invention relates to a diagnostic marker for systemic lupus erythematosus, and in particular discloses application of a reagent for specific detection of high mannose type N-linked carbohydrate chain level in a serum antibody to preparation of a diagnostic tool for diagnosis and/or prognosis assessment of systemic lupus erythematosus. The increase of the high mannose type N-linked carbohydrate chain level in the serum antibody is closely related to the occurrence of systemic lupus erythematosus. Therefore, the diagnostic marker can be used for early diagnosis and/or prognostic assessment of systemic lupus erythematosus, and further can be used for guiding treatment of systemic lupus erythematosus.

The invention relates to a traditional Chinese medicine immunopotentiator (an astragalus polysaccharide immunopotentiator for short) prepared from astragalus extracts and sulfated epimedium polysaccharides, which belongs to the field of immunological adjuvants of livestock and poultry. 1,000ml of the liquid medicine is prepared from 40g of astragalus and 120g of epimedium herb. The preparation method of the immunopotentiator comprises the following steps of: decocting the astragalus with water for three times, then merging the obtained filter liquor and condensing the filter liquor into 500ml of astragalus solution; extracting the epimedium polysaccharides by using the epimedium herb water decoction and ethanol precipitate method, then decorating the polysaccharides by using the chlorosulfonic acid-pyridine method, and preparing the polysaccharides into 500ml of sulfated epimedium polysaccharide solution after carrying out distilled water dialysis on the polysaccharides; and mixing the astragalus solution and the sulfated epimedium polysaccharide solution, and then filtering, sub-packaging and sterilizing to obtain the traditional Chinese medicine astragalus polysaccharide immunopotentiator. The immune experiment shows that the astragalus polysaccharide immunopotentiator has the advantage of obviously improving the proliferation of peripheral blood lymphocyte of chicken and enhancing the cellular immunity, obviously improving the potency of a serum antibody, promoting the lymphocyte proliferation, enhancing the cellular immunity and humoral immunity, and improving the immune response of a vaccine by coordinately immunizing chickling by using the Newcastle disease vaccine.

This invention relates to a method for stimulation or an activation of immunological function directed to activate natural killer cells and macrophages or increase production of serum antibody in a patient in need of such stimulation or activation, comprising administering an isolated and/or purified polypeptide of a fungal immunomodulatory protein. This invention also relates to a method for suppressing proliferation of a cancer cell and a method for suppressing a tumor cell mobility, comprising providing to the tumor cell a purified polypeptide of a fungal immunomodulatory protein.

The invention discloses an indirect ELISA method and kit for detecting serum 3-type duck hepatitis virus a antibody and belongs to the technical field of serum antibody detection. The indirect ELISA method includes that serum 3-type duck hepatitis virus VP1 protein is utilized as an envelope antigen with the peridium quantity as 0.1-1mug per hole, HRP-mice anti-duck IgY is utilized as the HRP with the use concentration as 0.2-2mug/mL, and the coloration time is 10 minutes. The kit comprises a VP1 protein antigen envelope board, the HRP-mice anti-duck IgY, sample diluent, a scrubbing solution, TMB solutions A and B and a stop solution. The method and the kit can be used for detecting the serum 3-type duck hepatitis virus a antibody in duck serum and duck egg yolk, and the serum does not have cross reaction with positive serum of other viruses. Compared with a traditional neutral reaction detection method, the method has the advantage of being convenient and accurate.

The invention provides a vaccine composition, a preparation method and an application thereof. The vaccine composition includes: an immune dose of porcine circovirus 2-type antigen, an immune dose of porcine Japanese encephalitis virus antigen, an immune dose of porcine parvovirus antigen and an adjuvant. The vaccine composition can effectively prevent and cure postweaning piglet multisystemic syndrome and sow reproduction dysfunctional diseases which are caused by 2-type porcine circovirus, porcine Japanese encephalitis virus and porcine parvovirus. An immune effect of the vaccine composition is better than that of a single vaccine. The vaccine composition is little in side effects, is high in valence of a serum antibody, has a long immune period, can save time and labor intensity, has a small stress response to a pig, can simplify immunity processes and can reduce production cost and prevention cost.

The invention discloses a kit for detecting a capripoxvirus serum antibody based on a synthetic peptide. A preparation method of the kit comprises the following steps of 1, designing a short-peptide aiming at a capripoxvirus main immunogene P32, 2, synthesizing a peptide fragment by a conventional peptide synthesis technology, 3, preparing the kit for detecting a capripoxvirus serum antibody based on a synthetic peptide, and 4, optimizing conditions and finishing the preparation of the kit for detecting a capripoxvirus serum antibody. A coating antigen adopted by the kit is an external synthetic immunoactive peptide fragment, reduces the danger of totvirus use and prevents virus diffusion and escape. The synthetic peptide adopted by the kit has high purity, has immunological characteristics similar to capripoxvirus particles, and can replace capripoxvirus particles and be used as an antigen for detection and thus the kit realizes sensitive, specific, safe and reliable detection of a capripoxvirus serum antibody.

The invention relates to a method of utilizing yolk antibody instead of serum antibody to evaluate infection state of breeder flock. The method of the invention comprises the following steps: collecting chicken serum and eggs, respectively; respectively detecting antibody levels of serum and yolk by REV, REOV, ALV-J, ALV-AB, CAV and IBDV enzyme linked immunosorbent assay (ELISA) kits from IDEXX company; comparatively analyzing serum and yolk antibody OD value correlation coefficient by SPSS Statistics 17.0 to obtain correlation coefficient of an optimum dilution factor of yolk antibody and a serum antibody OD value according to ELISA detection. The detecting result further indicates that the positive and negative result consistent rate of yolk sample and the serum sample at the optimum yolk dilution factor is 96%-100%. The result of the invention indicates that the serum samples can be replaced by yolk when various infection states of breeder flock are detected by ELISA kits provided by IDEXX for detection with serum samples, so that the infection state of breeder flock can be detected by detecting yolk antibody level.

The invention relates to an indirect enzyme-linked immunosorbent assay (ELISA) method for detecting a duck flavivirus serum antibody, which is characterized in that: duck flavivirus is used as an envelop antigen, and an indirect ELISA method for detecting duck flavivirus serum antibody in duck blood serum is established. The method can effectively diagnose the duck flavivirus which is prevalent at present in China and can carry out large-scale investigation of blood serum epidemiology, and a quick, simple and convenient detection method can be provided for controlling the prevention and the prevalent situation of the duck flavivirus.

The invention is directed to a microarray assay procedure that can be used for profiling the antibodies present in serum, plasma or blood. The assay may be used to identify antibodies and antigens that are characteristic of particular diseases or conditions. In addition, the invention includes specific antigens that are associated with prostate cancer, progressive benign prostate hyperplasia (BPH) and ovarian cancer.